Stay connected and up-to-date on the latest news and reports. It’s never been easier to know what’s going on in digital health.
2024 has been off to a great start at HealthXL, with topics ranging from Tech Enabled Change in Oncology Workflows to a Masterclass: The Legacy of Pear Therapeutics
Read more
ViVE has always been an essential event for digital health decision-makers, offering invaluable insights into the evolving landscape of healthcare.
Read more
2024 has been off to a great start at HealthXL, with topics ranging from How to Scale Partnerships Between Lifesciences and Digital Health Companies? to Real World Data in Clinical Trials: Benefits and Best Practices.
Read more
AI holds the promise of revolutionising clinical trials, specifically by automating and optimising critical processes. The technology has the capability to significantly boost productivity, cut costs, and accelerate the overall timeline of clinical trials.
Read more.png)
Many of you may still be relishing in the holiday bliss, but for HealthXL, the new year is already in full swing. Before we properly close the door on last year, I wanted to take a minute (or so …) to reflect on the tumultuous year that has been.
Read more
As the year draws to a close so does our AI spotlight series. The series catered to many different interests with topics and conversations focused on themes such as Does AI Guarantee ROI and Revolutionising Pharma: AI's Impact on the Value Chain.
Read more
The HealthXL community convened in Princeton, New Jersey. In collaboration with Otsuka, HealthXL organised its fourth Global Gathering of the year around the theme of Leveraging Data-Driven Strategies for Improving Patient Experience.
Read more
By embracing digital measures, pharma can accelerate drug development and improve patient outcomes. Pharma can and will continue to compete on assets, but should not compete on (digital) endpoints. We require industry collaborations in order to usher in a new era of medicine.
Read more
It's been another month of great events at HealthXL, with topics ranging from Enhancing Patient Experiences with Data-Driven Insights to PDT 2.0: The Future of Prescription Digital Therapeutics. To make sure you don't miss the top insights from our community meetings, here are my top five takeaways.
Read more
In a recent masterclass, the discussion revolved around approaches, scalability, and accessibility of digital health solutions in GLP-1 medication and obesity management. In this article, we highlight the key insights shared during the session.
Read more%20(1).png)
In this week’s blog, guest author Ahmed Albaiti (Principal, ZS), makes a case for why the recent wave of bad news in digital health may just be the focused push that the industry needs.
Read more%20(2).png)
In the recent years, patient engagement has gained great popularity in healthcare. The most impactful and adoptable solutions come from involving patient experts, key opinion leaders and other key stakeholders in a collaborative 'co-creation' process.
Read more.png)
Our HealthXL meetings in April covered everything from ‘Data Monetisation for MedTech Companies’ to ‘The Potential of OTC DTx Solutions’. To make sure you’re not missing out on the top insights from our communities, and get a sneak peak at some of the conversations, here are my top five takeaways.
Read more.png)
DTx solutions have been developed, theoretically, to remove many of the barriers associated with traditional care models and be more scalable and readily available. However, these solutions are not always accessible or inclusive for the populations that could benefit from them the most.
Read more.png)
Pharma-DTx partnerships can be a good strategy when both the pharma and the DTx companies speak the same language. While successful pilots have been demonstrated, there are challenges in scaling and sustaining innovations that generate value and return on investment (ROI) for pharma companies.
Read more.png)
Our HealthXL meetings in March covered everything from ‘Navigating the DiGA Framework’ to ‘Leveraging Sources of US Government Funding for Digital Health’. Make sure you’re not missing out on the topics that matter the most to our communities and are plugged into the conversation.
Read more.png)
Over the past decade, pharma’s interaction with digital health has grown more sophisticated and purposeful. In the last year however, innovation wrapped around the drug has become the object of budgetary scrutiny in pharmaceutical companies. So why continue to invest in digital health?
Read more.png)
In this blog we analyse the current landscape of RNA therapeutics and postulate on where best digital health may support this innovative area of medicine.
Read more